Nath Bio-GenesQ3 FY25Agricultural Food & other Products

Nath Bio-Genes

Q3 FY25 Earnings Call Analysis

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Future growth expectations for Nath Bio-Genes (India) Limited: - Targeting around 15% top-line growth over last year for H2 FY '26 (Devinder Khurana). - Aspirations to cross INR 400 crores revenue this year and potentially INR 500 crores next year, implying 15-20% growth (Devinder Khurana). - Vegetable seeds are fastest-growing, expected to grow ~25% Y-o-Y due to strong demand. - Maize volumes showed ~17% recovery in H1 FY '26; expected to continue growing 3-4x over next year (Harish Pandey). - Cotton portfolio growing ~6% in volume and 26.3% in value, market share gains observed. - Continuous R&D efforts aimed at launching superior products annually over next 3-4 years. - Plant Nutrition Solutions segment expecting growth driven by favorable monsoon and farmer demand. - Top line expected to show steady improvement subject to monsoon patterns and product performance. Overall, the company maintains a positive growth outlook with a focus on product innovation and market expansion.

Margin guidance

Category 3

→Management expects around 15% revenue growth over the previous year for FY '26, with an aspirational target of reaching INR 500 crores revenue next year (FY '27), implying 15-20% growth potential.
→Bottom line expected to improve accordingly; if revenue hits INR 500 crores, bottom line could be approximately INR 100 crores, improving EPS and intrinsic value of shares.
→EBITDA margins have slightly decreased due to higher credit extended to customers but expected to improve once the market stabilizes and credit sales reduce.
→Management plans continued operational improvements and R&D investments to drive product acceptance and market share, supporting sustained growth.
→Dividend payouts have been consistent and are expected to increase if profits improve.
→Overall, management is confident of better operating and net profit margins with a steady year-on-year growth trajectory in coming years.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Nath Bio-Genes and 1,400+ other companies.

Fundraise plans

- No current or planned fundraising through debt or equity was mentioned during the conference call. - Specifically, on the Philippines project, the company stated they are not investing money currently, only time and energy are being spent to obtain government permissions. - Management emphasized operational improvement and internal growth rather than raising external capital. - No reference to new debt issuances or equity offerings was made in responses related to financial strategy. - The company is focusing on organic growth, enhancing R&D, and improving products to increase revenues and profits. - Promoters hold 50% stake and do not actively intervene in market pricing, indicating confidence in existing capital structure. Overall, Nath Bio-Genes currently appears to rely on internal resources and operational efficiencies rather than new fundraising.

Order book

→As of the conference call dated November 14, 2025, Nath Bio-Genes did not explicitly state the exact current order book or pending orders.
→However, it was mentioned that there is around INR 100 crores of advanced booking lying in their books, yet to be adjusted against receivables.
→The company expects that these advanced bookings, along with recoveries from the market, will reduce debtor levels.
→Stock levels accumulated this year are expected to be either maintained or slightly increased, manageable for Kharif 2026 sales.
→Overall, the company is prepared for demand in upcoming seasons, with product sales anticipated to grow, supported by ongoing operational improvements and product acceptance by farmers.

Capex plans

Yes

→No new capital investment is being made currently in the Philippines as government permissions are pending; only time and energy are being invested to secure approvals (Page 17).
→The company is focusing on research and development (R&D) with increased investments to develop superior and innovative products; significant product registration efforts are ongoing under the Plant Varieties Protection Act (Pages 14 and 7).
→There is no plan to sell Aurangabad land; it will continue to be used for seed cultivation and retained as a valued asset (Page 14).
→A strategic focus remains on developing and launching new products across segments over the next 3-4 years to drive growth (Page 7).
→The Uzbekistan joint venture is progressing with product evaluation, parallel seed production, and building a marketing structure (Page 14).
→No explicit mention of large-scale future capex targets or investments beyond these ongoing efforts was provided.

How does Nath Bio-Genes rank vs peers in Agricultural Food & other Products?

Pro feature

1Nath Bio-Genes

Rev 3Mar 3

See full Agricultural Food & other Products sector rankings

Unlock with Pro

Want more stocks like Nath Bio-Genes?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio